Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

Catherine Lee, Doris Ponce, Zhenyi Xue, Nandita Khera, Betty K. Hamilton, Shawnta Lorthridge-Jackson, Valkal Bhatt, John Galvin, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2025-2446

Published: 2025

Journal Articles

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Carrie Kitko, Amandeep Salhotra, Mi Kwon, Zhenyi Xue, Valkal Bhatt, John Galvin, Patrick Hardesty, Silvia Mosher, Daniel Wolff

Blood (2025) 146 (Supplement 1): 6010.

https://doi.org/10.1182/blood-2025-6010

Published: 2025

Journal Articles

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL

Stephen Oh, Michael Grunwald, TaeHyung (Simon) Kim, Erin Crowgey, J.E. Hamer-Maansson, Ahmad Naim, Valkal Bhatt, Jeffrey Zwicker

Blood (2025) 146 (Supplement 1): 3749.

https://doi.org/10.1182/blood-2025-3749

Published: 2025

Journal Articles

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

Naveen Pemmaraju, Alexis Garduno, Jennifer Repp, Shayna Adams, Taylor Schwartz, Ahmad Naim, Valkal Bhatt, Jingbo Yu

Blood (2025) 146 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2025-2826

Published: 2025

Journal Articles

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis

Jingbo Yu, Nicole Engel-Nitz, Mary DuCharme, Jordan Fortunato, John Galvin, Valkal Bhatt, Catherine Lee

Blood (2025) 146 (Supplement 1): 2452.

https://doi.org/10.1182/blood-2025-2452

Published: 2025

Journal Articles

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Prithviraj Bose, Taylor Schwartz, Jennifer Repp, Alexis Garduno, Shayna Adams, Ahmad Naim, Valkal Bhatt, Jingbo Yu

Blood (2025) 146 (Supplement 1): 6391.

https://doi.org/10.1182/blood-2025-6391

Published: 2025

Journal Articles

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

Brandi Reeves, Marcelo Szymanski de Toledo, Fatima Trebak, Malgorzata Kasztan, Vimal Derebail, Rafal Pawlinski, Steffen Koschmieder, J.E. Hamer-Maansson, Ahmad Naim, Valkal Bhatt

Blood (2025) 146 (Supplement 1): 605.

https://doi.org/10.1182/blood-2025-605

Published: 2025

Journal Articles

Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study

Nosha Farhadfar, Maria Sola Soto, Saurabh Chhabra, Valkal Bhatt, Emily Andersen, Zhenyi Xue, Zachariah Defilipp

Blood (2025) 146 (Supplement 1): 272.

https://doi.org/10.1182/blood-2025-272

Published: 2025

Journal Articles

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States

Jingbo Yu, Kristin J. Moore, Nicole M. Engel-Nitz, Mary DuCharme, Britnie Thomas, John Galvin, Valkal Bhatt

Blood (2024) 144 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2024-208047

Published: 2024

Journal Articles

Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal

Stephen T. Oh, Jeffrey I. Zwicker, Kamal Patel, Erin L. Crowgey, Cynthia Timmers, Patricia Feldman, Justine Carl, J.E. Hamer-Maansson, Valkal Bhatt, Evan M. Braunstein, Michael R. Grunwald

Blood (2024) 144 (Supplement 1): 3145.

https://doi.org/10.1182/blood-2024-199195

Published: 2024

Journal Articles

Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States

Jingbo Yu, Kristin J. Moore, Nicole M Engel-Nitz, Mary DuCharme, John Galvin, Valkal Bhatt, Catherine J. Lee

Blood (2024) 144 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2024-200781

Published: 2024

Journal Articles

Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications

Pankit Vachhani, Jennifer Repp, JE Hamer-Maansson, Evan M. Braunstein, Valkal Bhatt, Haifa Kathrin Al-Ali

Blood (2024) 144 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2024-203924

Published: 2024

Journal Articles

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Doris M. Ponce, Areej El-Jawahri, Betty K. Hamilton, Nandita Khera, Valkal Bhatt, John Galvin, Catherine J. Lee

Blood (2023) 142 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2023-178073

Published: 2023

Journal Articles

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Michael Pratta, Angelina Volkova, Maureen Bleam, Rodica Morariu-Zamfir, Beth Rumberger, Stephen Douglass, Susan H. Smith, Valkal Bhatt, John Galvin, Annie Im, Sophie Paczesny, Kirk R. Schultz, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2023-174955

Published: 2023

Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Gérard Socié, Zhenyi Xue, Valkal Bhatt, John Galvin, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4765–4766.

https://doi.org/10.1182/blood-2022-169717

Published: 2022

Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Robert Zeiser, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli

Blood (2022) 140 (Supplement 1): 10507–10508.

https://doi.org/10.1182/blood-2022-170186

Published: 2022

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140541

Published: 2020

Journal Articles

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Blood (2019) 134 (Supplement_1): 5830.

https://doi.org/10.1182/blood-2019-127402

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States

Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal

Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States

Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only